These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

994 related items for PubMed ID: 16916765

  • 1. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG.
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [Abstract] [Full Text] [Related]

  • 2. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H.
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [Abstract] [Full Text] [Related]

  • 3. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P.
    Scand J Urol Nephrol; 2007 Aug; 41(6):456-77. PubMed ID: 17934985
    [Abstract] [Full Text] [Related]

  • 4. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].
    Arrizabalaga Moreno M, García González JI, Diez Rodríguez JM, Esteban Artiaga R, Castro Pita M, Navarro Sebastian J, Mora Durbán M, Paniagua Andrés P.
    Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.
    Cancer; 2007 Apr 01; 109(7):1273-8. PubMed ID: 17315165
    [Abstract] [Full Text] [Related]

  • 8. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.
    Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P.
    J Urol; 2002 Aug 01; 168(2):509-13. PubMed ID: 12131299
    [Abstract] [Full Text] [Related]

  • 9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 01; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
    Ryan CJ, Elkin EP, Cowan J, Carroll PR.
    Cancer; 2007 Jul 01; 110(1):81-6. PubMed ID: 17516446
    [Abstract] [Full Text] [Related]

  • 14. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H.
    BJU Int; 2008 Jan 01; 101(2):170-4. PubMed ID: 18173824
    [Abstract] [Full Text] [Related]

  • 15. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW.
    J Clin Oncol; 2003 Nov 01; 21(21):4001-8. PubMed ID: 14581423
    [Abstract] [Full Text] [Related]

  • 16. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.
    J Urol; 2006 Dec 01; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA, Cowan JE, Smith JA, Carroll PR, CaPSURE Investigators.
    J Urol; 2008 Oct 01; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [Abstract] [Full Text] [Related]

  • 19. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
    Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E, South-East Region Prostate Cancer Group.
    Cancer; 2005 Mar 01; 103(5):943-51. PubMed ID: 15651057
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors.
    Robinson D, Aus G, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E.
    Scand J Urol Nephrol; 2007 Mar 01; 41(2):103-9. PubMed ID: 17454947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.